Submit Your Feeds

Business News • PR NewsWire • Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration

Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration

CLEVELAND, April 28, 2011 /PRNewswire/ -- A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD)

View More : http://www.prnewswire.com/news-releases/cleveland-clinic-led-study-finds-bevacizumab-as-effective-as-fda-approved-ranibi...
Releted News by prnewswire
Cymer to Present at Upcoming Technology Conferences
MWW Group Promotes Brett White to Vice President
US Labor Department's Office of Disability Employment Policy announces 2011 theme for National Disability Employment Awareness Month
Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
ProLogis Updates Ownership and Tender Results for Ordinary Units in ProLogis European Properties
Home Sitemap Contact Us
© businessNewsNewsNews.com